Singapore markets closed

BiondVax Pharmaceuticals Ltd (2F50.SG)

Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
4.04000.0000 (0.00%)
At close: 08:08AM CEST
Show:
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
0
0
0
0
0
-
Operating expenses
Research development
5,210
5,210
5,765
3,249
16,004
-
Selling general and administrative
4,505
4,505
5,296
7,625
5,018
-
Total operating expenses
9,706
9,706
11,061
10,862
-2,281
-
Operating income or loss
-9,706
-9,706
-11,061
-10,862
2,281
-
Interest expense
-
-
-
3,486
348.9294
4,308
Total other income/expenses net
3,091
3,091
2,235
-487
-3,305
-
Income before tax
-6,500
-6,500
-5,796
-8,206
-1,385
-
Income from continuing operations
-6,500
-6,500
-5,796
-8,206
-1,385
-
Net income
-6,500
-6,500
-5,796
-8,206
-1,385
-
Net income available to common shareholders
-6,500
-6,500
-5,796
-8,206
-1,385
-
Basic EPS
-4.40
-16.00
-40.00
-80.00
-12.44
-
Diluted EPS
-4.40
-16.00
-40.00
-80.00
-12.44
-
Basic average shares
3,641
390.657
188.519
141.144
110.815
-
Diluted average shares
3,641
390.657
188.519
141.144
110.815
-